Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale

[1]  Dan J Stein,et al.  Genome-wide association study of over 40,000 bipolar disorder cases provides new insights into the underlying biology , 2021, Nature Genetics.

[2]  Paul J. Harrison,et al.  6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records , 2021, The Lancet Psychiatry.

[3]  E. Schulze-Bahr,et al.  New Cav1.2 Channelopathy with High-Functioning Autism, Affective Disorder, Severe Dental Enamel Defects, a Short QT Interval, and a Novel CACNA1C Loss-of-Function Mutation , 2020, International journal of molecular sciences.

[4]  S. Ripke,et al.  Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia , 2020, medRxiv.

[5]  Daniel L. Koller,et al.  Polygenic risk for anxiety influences anxiety comorbidity and suicidal behavior in bipolar disorder , 2020, Translational Psychiatry.

[6]  M. Vallecillo-Capilla,et al.  Preoperative oral pregabalin for anxiety control: a systematic review , 2020, Clinical Oral Investigations.

[7]  M. Owen,et al.  Translating insights from neuropsychiatric genetics and genomics for precision psychiatry , 2020, Genome Medicine.

[8]  Dan J Stein,et al.  Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis , 2020, Acta Neuropsychiatrica.

[9]  P. Sullivan,et al.  Reproducible Genetic Risk Loci for Anxiety: Results From ∼200,000 Participants in the Million Veteran Program. , 2020, The American journal of psychiatry.

[10]  Paul J. Harrison,et al.  Cellular calcium in bipolar disorder: systematic review and meta-analysis , 2019, Molecular Psychiatry.

[11]  A. Brett,et al.  Gabapentinoids for Pain: Potential Unintended Consequences. , 2019, American family physician.

[12]  A. Mowla,et al.  Pregabalin augmentation for resistant obsessive–compulsive disorder: a double-blind placebo-controlled clinical trial , 2019, CNS Spectrums.

[13]  Andrea Cipriani,et al.  Personalise antidepressant treatment for unipolar depression combining individual choices, risks and big data (PETRUSHKA): rationale and protocol , 2019, Evidence-Based Mental Health.

[14]  Gerta Rücker,et al.  How to perform a meta-analysis with R: a practical tutorial , 2019, Evidence-Based Mental Health.

[15]  D. Sharp,et al.  Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden , 2019, BMJ.

[16]  Umer Farooq,et al.  Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review , 2019, Front. Psychiatry.

[17]  A. Brett,et al.  A Clinical Overview of Off-label Use of Gabapentinoid Drugs. , 2019, JAMA internal medicine.

[18]  N. Freemantle,et al.  Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis , 2019, The Lancet.

[19]  Hunna J. Watson,et al.  Genome wide meta-analysis identifies genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders , 2019, bioRxiv.

[20]  G. Lewis,et al.  Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric Hospitalization and Self-Harm in Individuals With Serious Mental Illness , 2019, JAMA psychiatry.

[21]  S. Grover,et al.  Comorbidity of bipolar and anxiety disorders: An overview of trends in research , 2019, World journal of psychiatry.

[22]  F. Montastruc,et al.  Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017 , 2018, JAMA.

[23]  A. Dolphin.  Voltage-gated calcium channel α 2δ subunits: an assessment of proposed novel roles , 2018, F1000Research.

[24]  L. Wilkinson,et al.  CACNA1C: Association With Psychiatric Disorders, Behavior, and Neurogenesis , 2018, Schizophrenia bulletin.

[25]  Yuki Sakai,et al.  A common brain network among state, trait, and pathological anxiety from whole-brain functional connectivity , 2018, NeuroImage.

[26]  S. Comai,et al.  Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery , 2018, Pharmacological Reviews.

[27]  David M. Maclean,et al.  The α2δ-1-NMDA Receptor Complex Is Critically Involved in Neuropathic Pain Development and Gabapentin Therapeutic Actions , 2018, Cell reports.

[28]  Paul J. Harrison,et al.  Long-read sequencing reveals the complex splicing profile of the psychiatric risk gene CACNA1C in human brain , 2018, bioRxiv.

[29]  Paul J. Harrison,et al.  The Emerging Neurobiology of Bipolar Disorder , 2018, Trends in Neurosciences.

[30]  R. Morgan,et al.  Treatment of Generalized Anxiety Disorder with Gabapentin , 2017, Case reports in psychiatry.

[31]  U. Bonnet,et al.  How addictive are gabapentin and pregabalin? A systematic review , 2017, European Neuropsychopharmacology.

[32]  G. Rücker,et al.  Methods for including information from multi‐arm trials in pairwise meta‐analysis , 2017, Research synthesis methods.

[33]  EE Morrison,et al.  Gabapentin and Pregabalin: Do the Benefits Outweigh the Harms? , 2017, The journal of the Royal College of Physicians of Edinburgh.

[34]  W. van den Brink,et al.  Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study , 2017, PLoS medicine.

[35]  A. Brett,et al.  Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern? , 2017, The New England journal of medicine.

[36]  Paul J. Harrison,et al.  Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis , 2017, BMJ Open.

[37]  A. Dolphin.  Voltage‐gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology , 2016, The Journal of physiology.

[38]  A. Pottegård,et al.  Abuse Potential of Pregabalin , 2016, CNS Drugs.

[39]  M. Owen,et al.  Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders , 2015, Progress in Neurobiology.

[40]  P. Monroe Butler,et al.  Gabapentin Therapy in Psychiatric Disorders: A Systematic Review. , 2015, The primary care companion for CNS disorders.

[41]  G. Hosseini,et al.  Effect of Pregabalin Augmentation in Treatment of Patients with Combat-Related Chronic Posttraumatic Stress Disorder: A Randomized Controlled Trial , 2014, Journal of psychiatric practice.

[42]  T. Roth,et al.  A randomized, double-blind, placebo-controlled, multicenter, 28-day, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. , 2014, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[43]  T. Roth,et al.  A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. , 2014, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[44]  P. Fitzgerald,et al.  Impact of comorbid anxiety disorders and obsessive-compulsive disorder on 24-month clinical outcomes of bipolar I disorder. , 2014, Journal of affective disorders.

[45]  Jiming Liu,et al.  Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range , 2014, BMC Medical Research Methodology.

[46]  L. Arnold,et al.  A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions. , 2014, Sleep medicine reviews.

[47]  Alexandra Pinggera,et al.  L-type Ca2+ channels in heart and brain , 2014, Wiley interdisciplinary reviews. Membrane transport and signaling.

[48]  Jianxin Shi,et al.  Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs , 2013, Nature Genetics.

[49]  Gordon H Guyatt,et al.  Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study. , 2013, Journal of clinical epidemiology.

[50]  D. Baldwin,et al.  Pregabalin for the treatment of generalized anxiety disorder: an update , 2013, Neuropsychiatric disease and treatment.

[51]  T. Nordahl,et al.  An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder. , 2013, Journal of affective disorders.

[52]  Laura B. Bragdon,et al.  The evidence-based pharmacotherapy of social anxiety disorder. , 2013, The international journal of neuropsychopharmacology.

[53]  M. Berridge.  Dysregulation of neural calcium signaling in Alzheimer disease, bipolar disorder and schizophrenia , 2013, Prion.

[54]  G. Zaccara,et al.  The adverse event profile of pregabalin across different disorders: a meta-analysis , 2012, European Journal of Clinical Pharmacology.

[55]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[56]  J. Greist,et al.  Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study , 2011, International clinical psychopharmacology.

[57]  G. Guyatt,et al.  GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.

[58]  A. Dolphin,et al.  The α2δ Ligand Gabapentin Inhibits the Rab11-Dependent Recycling of the Calcium Channel Subunit α2δ-2 , 2010, The Journal of Neuroscience.

[59]  H. Wittchen,et al.  Pregabalin reduces sleep disturbance in patients with generalized anxiety disorder via both direct and indirect mechanisms , 2010 .

[60]  D. Nutt,et al.  Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model , 2009, Journal of psychopharmacology.

[61]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[62]  J. Grafman,et al.  Neural correlates of anxiety in healthy volunteers: a voxel-based morphometry study. , 2009, The Journal of neuropsychiatry and clinical neurosciences.

[63]  R. Zucker,et al.  A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. , 2008, Alcoholism, clinical and experimental research.

[64]  K. Watschinger,et al.  Pharmacological disruption of calcium channel trafficking by the α2δ ligand gabapentin , 2008, Proceedings of the National Academy of Sciences.

[65]  A. Young,et al.  Anticonvulsant treatments of dysphoric mania: a trial of gabapentin, lamotrigine and carbamazepine in Iran , 2008, Neuropsychiatric disease and treatment.

[66]  A. Etkin,et al.  Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. , 2007, The American journal of psychiatry.

[67]  E. Vieta,et al.  A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. , 2006, The Journal of clinical psychiatry.

[68]  S. Priori,et al.  CaV1.2 Calcium Channel Dysfunction Causes a Multisystem Disorder Including Arrhythmia and Autism , 2004, Cell.

[69]  B. Mcfarland,et al.  Gabapentin use in a managed medicaid population. , 2002, Journal of managed care pharmacy : JMCP.

[70]  K. Lee,et al.  Gabapentin-mediated inhibition of voltage-activated Ca2+ channel currents in cultured sensory neurones is dependent on culture conditions and channel subunit expression , 2002, Neuropharmacology.

[71]  M. Frye,et al.  A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. , 2000, Journal of clinical psychopharmacology.

[72]  P. Suppes,et al.  Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. , 2000, Bipolar disorders.

[73]  M. Pollack,et al.  Placebo-controlled study of gabapentin treatment of panic disorder. , 2000, Journal of clinical psychopharmacology.

[74]  J. Davidson,et al.  Treatment of social phobia with gabapentin: a placebo-controlled study. , 1999, Journal of clinical psychopharmacology.

[75]  Humphrey D L Birley,et al.  Implicit memory , 1994, BMJ.

[76]  Julian P T Higgins,et al.  Association Between Risk-of-Bias Assessments and Results of Randomized Trials in Cochrane Reviews: The ROBES Meta-Epidemiologic Study , 2017, American journal of epidemiology.

[77]  F. Hofmann,et al.  L-type CaV1.2 calcium channels: from in vitro findings to in vivo function. , 2014, Physiological reviews.

[78]  S. Quello,et al.  Gabapentin treatment for alcohol dependence: a randomized clinical trial. , 2014, JAMA internal medicine.

[79]  Paul J. Harrison,et al.  Annals of the New York Academy of Sciences Innovative Approaches to Bipolar Disorder and Its Treatment , 2022 .